Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease
- 27 May 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 69 (4) , 1213-1220
Abstract
Background: Brevican, neurocan, tenascin-C, and tenascin-R are extracellular matrix (ECM) proteins that are mainly expressed in the brain. They play important roles in proliferation and migration of neurons and other cell types in the brain. These ECM proteins may also be involved in various pathologies, including reactive gliosis. Objective: The aim of the study was to investigate if ECM protein concentrations in cerebrospinal fluid (CSF) are linked to the neurodegenerative process in Alzheimer’s disease (AD). Methods: Lumbar CSF samples from a non-AD control group ( n = 50) and a clinically diagnosed AD group ( n = 42), matched for age and gender, were analyzed using commercially available ELISAs detecting ECM proteins. Mann-Whitney U test was used to examine group differences, while Spearman’s rho test was used for correlations. Results: Brevican, neurocan, tenascin-R, and tenascin-C concentrations in AD patients did not differ compared to healthy controls or when the groups were dichotomized based on the Aβ 42/40 cut-off. CSF tenascin-C and tenascin-R concentrations were significantly higher in women than in men in the AD group ( p = 0.02). Conclusion: ECM proteins do not reflect AD-pathology in CSF. CSF tenascin-C and tenascin-R upregulation in women possibly reveal sexual dimorphism in the central nervous system immunity during AD.Keywords
This publication has 47 references indexed in Scilit:
- Tenascins and inflammation in disorders of the nervous systemAmino Acids, 2012
- Current and future treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders, 2012
- Tenascins and the Importance of Adhesion ModulationCold Spring Harbor Perspectives in Biology, 2011
- Abnormal post‐translational and extracellular processing of brevican in plaque‐bearing mice over‐expressing APPswJournal of Neurochemistry, 2010
- Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: Amyloidogenesis and therapeutic strategies—A reviewJournal of Neuroscience Research, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Alzheimer's diseaseThe Lancet, 2006
- Amyloid β protein (Aβ) removal by neuroglial cells in cultureNeurobiology of Aging, 1995
- Proteoglycan-mediated Inhibition of Aβ ProteolysisJournal of Biological Chemistry, 1995
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984